logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Andrew Weickhardt

Chris O'Brien Lifehouse
H指数:36
被引数:8,280

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901)

ENZA-p研究中中期PSMA-PET总肿瘤体积对总生存期的预测价值，一项比较恩扎卢胺与恩扎卢胺联合[177Lu] Lu-PSMA-617（ANZUP1901）的随机Ⅱ期试验。

European Urology
IF25.2
2026-04-080
PRE
Louise Emmett; Nathan Papa; Oliver Sartor; Michael J. Morris; Shalini Subramaniam; Megan Crumbaker; Narjess Ayati; Jeffrey Chen; Ken Herrmann; Andrei Gafita; Mina Swiha; Anthony M. Joshua; Andrew Weickhardt; Sze-Ting Lee; Siobhan Ng; Roslyn J. Francis; Jeffrey C. Goh; David A. Pattison; Bao Ho; Sobia Khan
Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series

颅外、生殖腺外生殖细胞瘤：一项多中心澳大利亚病例系列研究

Asia-Pacific Journal of Clinical Oncology
IF1.6
2026-01-010
OAAI
Chow, Kar Ven Cavan; Conduit, Ciara; O'Haire, Sophie; Kuchel, Anna; Wong, Shirley; Grimison, Peter; Weickhardt, Andrew; Pranavan, Ganes; Lynam, James; Bastick, Patricia; Goh, Jeffrey; Sengupta, Shomik; Smith, Annabel; Liow, Elizabeth; Campbell, David; Wong, Ming; Zlatic, Kristina; Gibbs, Peter; Tran, Ben; Gan, Chun Loo
Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: Substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial

新型基于pembrolizumab的治疗方案作为晚期透明细胞肾细胞癌的一线疗法：开放标签、伞形平台、I/II期KEYMAKER-U03试验的子研究03A

Annals of Oncology
IF65.4
2025-10-180
PRE
C. Suarez; C. Rojas; S.J. Shin; P.Yanez Weber; L. Albiges; R. Motzer; H. Hammers; A. Peer; J-L. Lee; W.H. Miller; T. Waddell; V. Neiman; D. Keizman; A.Zwenger Kloster; A. Weickhardt; R. Dziadziuszko; L. Suttner; M. Sharma; J.E. Burgents; T. Powles
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

基线PSMA-PET总肿瘤体积和SUVmean在转移性去势抵抗性前列腺癌中的预后和预测价值：一项来自多中心、开放标签、随机、II期试验ENZA-p (ANZUP1901)的亚研究

lancet oncology
IF0
2025-07-300
PRE
Louise Emmett; Nathan Papa; Shalini Subramaniam; Megan Crumbaker; Andrew Nguyen; Anthony M Joshua; Shahneen Sandhu; Andrew Weickhardt; Sze-Ting Lee; Siobhan Ng; Roslyn J Francis; Jeffrey C Goh; David A Pattison; Thean Hsiang Tan; Ian D Kirkwood; Narjess Ayati; Claire Niu; Michael S Hofman; Andrew James Martin; Hayley Thomas; Ian D Davis; Martin R Stockler
TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations
EUROPEAN JOURNAL OF CANCER
IF7.1
2024-10-010
PRE
Loriot, Y.; Zhang, A.; Hansen, A.; Mantia, C.; Boni, V.; Weickhardt, A.; Yu, E. Y.; Robert, M.; Iyer, G.; Murtha, A.; Owens, S.; Suttle, B.; Vandekerkhove, G.; Wyatt, A.; Gammon, G.; Burn, T.; Tran, B.
UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)

UpFrontPSMA: 177Lu-PSMA-617和多西他赛 (D) 与多西他赛在转移性激素敏感性前列腺癌 (mHSPC) 中的随机II期研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Azad, A. A.; Bressel, M.; Tan, H.; Voskoboynik, M.; Suder, A.; Weickhardt, A. J.; Guminski, A.; Francis, R. J.; Saghebi, J.; Dhiantravan, N.; Joshua, A.; Emmett, L.; Murphy, D.; Hsiao, E.; Lee, S. T.; Pattison, D. A.; Nadebaum, D.; Kirkwood, I. D.; Hofman, M. S.
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
EUROPEAN UROLOGY ONCOLOGY
IF9.3
2024-06-012
PRE
Weickhardt, Andrew; Foroudi, Farshad; Lawrentschuk, Nathan; Xie, Jing; Sidhom, Mark; Pal, Abhijit; Grimison, Peter; Zhang, Alison; Ng, Siobhan; Tang, Colin; Hovey, Elizabeth; Chen, Colin; Hruby, George; Guminski, Alexander; McJannett, Margaret; Conduit, Ciara; Tran, Ben; Davis, Ian D.; Hayne, Dickon
A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Rosenberg, Jonathan; Sabatier, Renaud; Viceneux, Armelle; Rouge, Thibault De la Motte; Champiat, Stephane; Lebellec, Loic; Barthelemy, Philippe; Sonpavde, Guru; Gao, Xin; Niglio, Scot; Zhang, Tian; Gedye, Craig; Galsky, Matthew; Milowsky, Matthew; Reimers, Melissa; Weickhardt, Andrew; Grande, Enrique; Castellano, Daniel E.; Bilen, Mehmet; Patnaik, Amita; Zerbib, Robert; Balbas, Minna; Xu, Xiaojian; Aptaker, Kaitlyn; Balar, Arjun V.; Awada, Ahmad H.
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
ONCOIMMUNOLOGY
IF6.3
2023-12-208
OA
Lin, Chia-Chi; Garralda, Elena; Schoeffski, Patrick; Hong, David S.; Siu, Lillian L.; Martin, Miguel; Maur, Michela; Hui, Rina; Soo, Ross A.; Chiu, Joanne; Zhang, Tian; Ma, Brigette; Kyi, Chrisann; Tan, Daniel S. W.; Cassier, Philippe A.; Sarantopoulos, John; Weickhardt, Andrew; Carvajal, Richard D.; Spratlin, Jennifer; Esaki, Taito; Rolland, Frederic; Akerley, Wallace; Deschler-Baier, Barbara; Rispoli, Lawrence; Samant, Tanay S.; Chowdhury, Niladri Roy; Gusenleitner, Daniel; Kwak, Eunice L.; Askoxylakis, Vasileios; De Braud, Filippo
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort

患有去势抵抗性前列腺癌的老年人的治疗模式和结果: 对澳大利亚真实世界队列的分析

JOURNAL OF GERIATRIC ONCOLOGY
IF2.7
2023-11-017
PRE
Fernando, Michael; Anton, Angelyn; Weickhardt, Andrew; Azad, Arun A.; Uccellini, Anthony; Brown, Stephen; Wong, Shirley; Parente, Phillip; Shapiro, Julia; Liow, Elizabeth; Torres, Javier; Goh, Jeffrey; Parnis, Francis; Steer, Christopher; Warren, Mark; Gibbs, Peter; Tran, Ben
The PD-1-and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
NATURE MEDICINE
IF50
2023-10-1932
OAAI
Luke, Jason J.; Patel, Manish R.; Blumenschein, George R.; Hamilton, Erika; Chmielowski, Bartosz; Ulahannan, Susanna V.; Connolly, Roisin M.; Santa-Maria, Cesar A.; Wang, Jie; Bahadur, Shakeela W.; Weickhardt, Andrew; Asch, Adam S.; Mallesara, Girish; Clingan, Philip; Dlugosz-Danecka, Monika; Tomaszewska-Kiecana, Monika; Pylypenko, Halyna; Hamad, Nada; Kindler, Hedy L.; Sumrow, Bradley J.; Kaminker, Patrick; Chen, Francine Z.; Zhang, Xiaoyu; Shah, Kalpana; Smith, Douglas H.; De Costa, Anushka; Li, Jonathan; Li, Hua; Sun, Jichao; Moore, Paul A.
Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial

前列腺癌挽救性放射治疗前分子影像学对强化治疗患者选择的影响: PROPS试验的事后分析

CANCER IMAGING
IF3.5
2023-06-081
OAAI
Tremblay, Samuel; Alhogbani, Mofarej; Weickhardt, Andrew; Davis, Ian D.; Scott, Andrew M.; Hicks, Rodney J.; Metser, Ur; Chua, Sue; Davda, Reena; Punwani, Shonit; Payne, Heather; Tunariu, Nina; Ho, Bao; Young, Sympascho; Singbo, Mahukpe Narcisse Ulrich; Bauman, Glenn; Emmett, Louise; Pouliot, Frederic

研究方向

暂未获取到该数据
I
Ian D. Davis
H 指数:76论文数:694被引数:2.9万
A
Andrew M. Scott
H 指数:95论文数:1,215被引数:3.6万
B
Ben Tran
H 指数:38论文数:453被引数:6,571
A
Arun Azad
H 指数:51论文数:521被引数:1.3万
L
Louise Emmett
H 指数:54论文数:333被引数:1.3万
J
Jeffrey C. Goh
H 指数:18论文数:117被引数:3,236
D
D. Ross Camidge
H 指数:110论文数:999被引数:6.3万
R
Robert C. Doebele
H 指数:74论文数:534被引数:3.1万
E
Edmond M. Kwan
H 指数:23论文数:243被引数:3,049
P
Peter Grimison
H 指数:39论文数:286被引数:5,138